Protecflor launched in Belgium by Sanofi Aventis06/26/2009 Protecflor™ was introduced in Belgium by Sanofi Aventis under the brand name of ErcéFlora Supra. This is the tenth launch for Protecflor™ formula. This unique probiotic combines the synergistic activities of three well documented Rosell bacteria strains with Saccharomyces boulardii probiotic yeast. The synergistic effects of the probiotic yeast and bacteria components of Protecflor™ have been demonstrated in vivo in a rat model of traveller’s diarrhoea. Marketed by Sanofi Aventis through pharmacists as a food supplement, the probiotic is recommended for reinforcing or restoring the intestinal barrier and for fighting intestinal infections, in particular traveller’s diarrhoea. Its launch coincides with the summer season, when traveller’s diarrhoea represents a holiday spoiler for up to 50% of those on the move (an estimated 5-50% of travellers suffer from the disorder, depending on the destination). Since its initial launch in 2007, Protecflor™ formula has already been introduced in nine other countries by key industry partners -- by Numedica in the U.S., by Wren in the UK, by Ivancic in Serbia, by CatMedia in Australia, and by Walmark in the Czech Republic, Romania, Hungary, Bulgaria and Poland.Nutrition Industry Executive: “Children’s Health Goes Natural “- April 200905/15/2009 Read or print the article on-line here.Nutraingredients.com: “Lallemand builds science behind probiotics for immune health”, video interview - May 15, 200905/15/2009 Nutraingredients reports on ProbioKid’s clinical trial during Vitafoods International trade show in Geneva. Click here to see the video interview by Stephen Daniells.ProbioKid®* Decreases the Risks of Common Infection Occurrences in Children05/13/2009 Results of a randomized double-blind placebo-controlled clinical study of Institut Rosell-Lallemand’s synbiotic were unveiled at the Vitafoods International Show in Geneva , May 7th, 2009. The clinical trial, conducted in partnership with Urgo, who distributes ProbioKid in France under brand name Immunostim®, aimed at evaluating the effects of key synbiotic ProbioKid® on the incidence of infectious episodes in children during the winter period. The study was conducted during the winter of 2006-2007 and involved 135 healthy, school-age children who had suffered from at least three episodes of ear-nose-throat (ENT), bronchopulmonary or gastric disorder during the course of the previous winter. The study found that a three-month daily supplementation with ProbioKid®* during the winter was able to reduce the risks of common infections in children. Fifty percent of the children in the synbiotic group did not develop any ENT, bronchopulmonary or gastric disorder during the winter vs. 32.9% of children in the placebo group (P<0.05). This represents a twenty-five percent reduction of the relative risk of infectious disease in the ProbioKid®* group compared to the placebo group (P<0.05). In addition, it was shown that only 25.8% of children in the synbiotic group missed at least one day of school vs. 42.5% in the placebo group (P<0.05). No treatment-related side-effects were reported. According to Isabelle Champié, Human Nutrition Brand Manager for Institut Rosell-Lallemand, “Immune support is an expanding market for probiotic applications, and there is mounting scientific evidence indicating their benefits. While we put every effort into the formulation and scientific documentation of our products (the individual probiotic strains that are used to formulate ProbioKid are well documented for their effects on the different levels of the immune response, and their effectiveness has been confirmed by various scientific studies), we are also strongly committed to conducting clinical studies on the finished product formula rather than individual strains.” Dr Jean-Charles Kerihuel, from Vertical (Paris, France), who presented the clinical study at Vitafoods International concluded: “ Our study strongly supports a positive effect of ProbioKid®*in the prevention of infectious episodes in children, and even though we do not have a clear picture of the synbiotic modes of action, it is clear that its benefits are linked to the strains used and the product formula, and these benefits cannot be extrapolated to other products.” ProbioKid®* formula combines an optimal blend of three well-documented probiotic strains — Rosell-52, Rosell-71 and Rosell-33 — with a prebiotic (FOS). It has been specially formulated to support a healthy intestinal flora, essential to maintaining the body’s natural defences. *distributed in France under brand name Immunostim®Biostime SAS launches Leseil Capsule in China04/24/2009 Through their Joint Venture Biostime France SAS, Institut Rosell-Lallemand and Biostime Inc, leader in the probiotic for children market in China, have just launched a first probiotic product, Leseil Capsule. This formula is aimed for helping to reduce intestinal disturbances that can appear during travels. For this occasion, Valérie Delahaye, Human Nutrition Deputy General Manager, gave an interview on the Chinese website sohu.com The discussion is available in English on: http://gd.sohu.com/s2009/interview-leseil/index.shtmlCPHI China04/10/2009 Institut Rosell-Lallemand will have a booth at one of the most important pharmaceutical exhibition in Asia, CPHI China, in Shanghai from June 23rd to 25th. Come and visit us at our booth E1A18 to discover our new offers. Nadine RENARD, Product manager strain and technologies and technical support manager at Institut Rosell-Lallemand, will hold on that occasion a conference called: "What is a good probiotic"? The session will be in the room E1-M11 from 13 H 30 to 14 H 30 on June 23rd 2009.Vitafoods04/02/2009 Vitafoods International is widely regarded as the flagship exhibition for the nutraceuticals industry, in 2008 the event attracted over 450 leading exhibiting companies and over 7000 attendees.Vitafoods Expo04/01/2009 Vitafoods International press release |
